TEMOVATE E Drug Patent Profile
✉ Email this page to a colleague
When do Temovate E patents expire, and what generic alternatives are available?
Temovate E is a drug marketed by Fougera Pharms and is included in one NDA.
The generic ingredient in TEMOVATE E is clobetasol propionate. Forty-four suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Temovate E
A generic version of TEMOVATE E was approved as clobetasol propionate by COSETTE PHARMS NC on February 16th, 1994.
US Patents and Regulatory Information for TEMOVATE E
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fougera Pharms | TEMOVATE E | clobetasol propionate | CREAM;TOPICAL | 020340-001 | Jun 17, 1994 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
